1. At standard clinical doses, organic nitrates produce their primary anti-ischemic benefit through which hemodynamic mechanism?
A) Arteriolar dilation reducing systemic vascular resistance and afterload, decreasing left ventricular wall stress during systole
B) Direct negative chronotropic effect on the sinoatrial node, reducing heart rate and myocardial oxygen consumption
C) Predominant venodilation of large capacitance veins, reducing venous return and left ventricular end-diastolic pressure, thereby decreasing myocardial wall stress and oxygen consumption
D) Dilation of coronary resistance arterioles, increasing microvascular blood flow to ischemic subendocardial territory
E) Inhibition of platelet aggregation via cyclic GMP elevation, reducing thrombus formation in stenotic coronary segments
ANSWER: C
Rationale:
The correct answer is C. At standard clinical doses, organic nitrates act predominantly on large capacitance veins rather than on arterioles or resistance vessels. Venodilation pools blood in the peripheral venous circulation, reducing venous return to the right heart and lowering right atrial pressure, left ventricular end-diastolic pressure (LVEDP), and ventricular volume. By the law of Laplace, wall stress is proportional to pressure and radius; reducing both decreases myocardial oxygen consumption (MVO2) and relieves subendocardial compressive forces, improving perfusion to the most vulnerable myocardial layer. This preload reduction is the dominant anti-ischemic mechanism at doses used clinically for stable angina.
Option A: Option A is incorrect: arteriolar dilation and afterload reduction are hemodynamic effects of nitrates, but occur only at higher doses — intravenous nitroglycerin above 50–100 mcg/min. Standard sublingual and oral doses produce negligible arteriolar effect.
Option B: Option B is incorrect: nitrates have no direct chronotropic effect on the sinoatrial node; they in fact cause reflex tachycardia via baroreceptor activation in response to the blood pressure reduction they produce, requiring concurrent beta-blocker therapy to counteract.
Option D: Option D is incorrect: nitrates dilate large epicardial coronary arteries — the critical mechanism in vasospastic angina — but do not consistently dilate coronary resistance arterioles (the microvasculature); they may provide little benefit in microvascular angina and carry a theoretical coronary steal risk at high doses.
Option E: Option E is incorrect: nitrates do modestly inhibit platelet aggregation via cGMP elevation in platelets, but this is a minor secondary effect that does not account for their primary anti-ischemic benefit and is not clinically comparable to dedicated antiplatelet agents.
2. Which of the following most accurately explains why isosorbide mononitrate extended-release (ISMN-ER) taken once daily at 7:00 AM is the preferred long-acting oral nitrate for most patients with chronic stable angina?
A) ISMN-ER achieves approximately 100% oral bioavailability because it does not undergo first-pass hepatic metabolism, delivers consistent plasma concentrations, and a single morning dose automatically creates an overnight nitrate-free interval of approximately 12 hours that prevents tolerance development
B) ISMN-ER is preferred because it has a faster onset of action than isosorbide dinitrate (ISDN), making it suitable for both acute relief and chronic prophylaxis from the same formulation
C) ISMN-ER is preferred because it undergoes hepatic conversion to an active metabolite with a half-life exceeding 24 hours, providing uninterrupted around-the-clock coverage without requiring a nitrate-free interval
D) ISMN-ER is preferred because randomized controlled trials have demonstrated that it reduces myocardial infarction risk and cardiovascular mortality in patients with stable coronary artery disease
E) ISMN-ER is preferred because its extended-release mechanism maintains plasma concentrations below the threshold for ALDH2 inactivation, allowing continuous 24-hour dosing without tolerance
ANSWER: A
Rationale:
The correct answer is A. Isosorbide mononitrate (ISMN) is the active mononitrate form of isosorbide dinitrate and does not require hepatic bioactivation or undergo significant first-pass hepatic extraction. Its oral bioavailability is approximately 100%, delivering plasma concentrations that are proportional to the administered dose and consistent between patients regardless of hepatic function — a substantial advantage over isosorbide dinitrate (ISDN), which has only approximately 25% bioavailability due to extensive first-pass extraction. The extended-release formulation taken at 7:00 AM provides anti-ischemic coverage through waking hours, and the drug effect wanes by approximately 7:00 PM, automatically creating an overnight nitrate-free interval of approximately 12 hours. This interval allows regeneration of mitochondrial aldehyde dehydrogenase 2 (ALDH2) and resolution of neurohormonal pseudotolerance, preventing efficacy loss. Once-daily dosing also maximizes adherence relative to eccentric twice-daily regimens.
Option B: Option B is incorrect: ISMN-ER has an onset of 30–60 minutes and is entirely unsuitable for acute angina relief; sublingual nitroglycerin (onset 1–3 minutes) remains the agent for acute attacks.
Option C: Option C is incorrect: ISMN is not a prodrug and does not undergo hepatic conversion to a longer-acting metabolite; its half-life is approximately 5 hours for the immediate-release form. ISMN-ER does not provide 24-hour coverage — the waning of effect is precisely what creates the therapeutic nitrate-free interval.
Option D: Option D is incorrect: no long-acting nitrate formulation has demonstrated mortality or myocardial infarction reduction in stable coronary artery disease; nitrates are anti-anginal and anti-ischemic agents only.
Option E: Option E is incorrect: there is no sub-threshold plasma concentration strategy that prevents ALDH2 inactivation with continuous nitrate exposure; the nitrate-free interval — not dose reduction — is the only reliably effective strategy to prevent tolerance.
3. A 76-year-old woman with severe aortic stenosis (valve area 0.6 cm²) develops exertional chest pain. Why are organic nitrates contraindicated in this patient?
A) Nitrates cause reflex tachycardia that increases the transvalvular pressure gradient across the stenotic aortic valve, worsening left ventricular outflow obstruction
B) Nitrates dilate the coronary ostia adjacent to the stenotic valve, paradoxically increasing turbulent flow and reducing effective coronary perfusion pressure
C) Nitrates produce excessive afterload reduction in aortic stenosis, reducing impedance to left ventricular ejection below the threshold needed to maintain coronary perfusion pressure
D) In severe aortic stenosis, fixed mechanical outflow obstruction prevents the compensatory increase in cardiac output that would normally offset nitrate-induced preload reduction; venodilation causes profound hypotension and risks syncope or hemodynamic collapse
E) Nitrates are contraindicated because the hypertrophied left ventricle in aortic stenosis is exquisitely sensitive to cyclic GMP-mediated calcium influx, causing paradoxical diastolic dysfunction
ANSWER: D
Rationale:
The correct answer is D. In severe aortic stenosis, the stenotic valve creates a fixed mechanical obstruction to left ventricular outflow. Under normal physiological conditions, a fall in venous return from venodilation triggers compensatory increases in heart rate and contractility to maintain cardiac output. In severe aortic stenosis, this compensation cannot occur because the fixed valve obstruction limits forward flow regardless of how forcefully the left ventricle contracts — the valve, not the myocardium, is the limiting factor for cardiac output. Nitrate-induced venodilation reduces preload and venous return; without the ability to compensate by increasing cardiac output, blood pressure falls precipitously. The result is severe hypotension with reduced coronary perfusion pressure in a hypertrophied ventricle that already has elevated oxygen demand, and high risk of syncope or hemodynamic collapse. Nitrates are therefore absolutely contraindicated in severe aortic stenosis.
Option A: Option A is incorrect: reflex tachycardia from nitrates is a real and problematic effect in aortic stenosis, but it does not increase the transvalvular gradient in a mechanically meaningful way; the primary contraindication mechanism is the inability to compensate for preload reduction.
Option B: Option B is incorrect: nitrates do not dilate coronary ostia directly adjacent to the stenotic valve in a manner that worsens turbulence or reduces coronary perfusion; epicardial coronary vasodilation occurs distal to the ostia.
Option C: Option C is incorrect: nitrates at standard doses produce predominantly venodilation (preload reduction), not arteriolar dilation (afterload reduction); afterload reduction would theoretically benefit aortic stenosis.
Option E: Option E is incorrect: cGMP does not cause paradoxical calcium influx in the hypertrophied left ventricular myocardium; cGMP mediates vascular smooth muscle relaxation and does not produce direct diastolic dysfunction.
4. A 69-year-old man prescribed a transdermal nitroglycerin patch 0.4 mg/hour reports that it stopped relieving his angina within one week of starting. His medication review reveals he wears the patch continuously without removing it. Which of the following correctly identifies the problem and its solution?
A) The patch has lost potency due to prolonged skin contact degrading the drug reservoir; the solution is to replace the patch every 48 hours rather than every 7 days
B) Continuous patch wear causes nitrate tolerance by preventing the nitrate-free interval required for ALDH2 regeneration and resolution of neurohormonal pseudotolerance; the solution is to apply the patch in the morning and remove it in the evening, providing a 10–12 hour overnight nitrate-free interval
C) Continuous wear causes skin receptor downregulation at the application site; the solution is to rotate application sites with each new patch while continuing continuous wear
D) The patch is ineffective because transdermal absorption is too slow to maintain plasma concentrations above the therapeutic threshold with continuous wear; the solution is to add a twice-daily oral nitrate to supplement the patch
E) Continuous wear is appropriate for the first month to establish stable plasma concentrations; tolerance only develops after three to six months of uninterrupted use, suggesting the patient has a genetic variant reducing ALDH2 expression
ANSWER: B
Rationale:
The correct answer is B. Failure to remove the transdermal nitroglycerin patch is one of the most common errors in outpatient nitrate prescribing. Continuous patch wear causes nitrate tolerance to develop within 24–48 hours of uninterrupted exposure through three mechanisms: oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) by reactive oxygen species generated during nitroglycerin bioactivation, neurohormonal pseudotolerance from renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) activation, and increased vascular superoxide production consuming nitric oxide (NO). The nitrate-free interval (NFI) is the only reliably effective strategy to prevent and reverse all three mechanisms. The standard instruction is to apply the patch in the morning (7:00–8:00 AM) and remove it in the evening (7:00–8:00 PM), providing a 10–12 hour overnight nitrate-free period. Patients must be explicitly counseled that removal is deliberate and protective. During the NFI, non-nitrate anti-ischemic coverage with a beta-blocker or non-dihydropyridine calcium channel blocker (CCB) should be maintained.
Option A: Option A is incorrect: transdermal NTG patches do not lose potency through skin contact degradation; the reservoir formulation maintains drug stability for the labeled wear period. More frequent replacement does not address the tolerance mechanism.
Option C: Option C is incorrect: skin receptor downregulation is not the mechanism of nitrate tolerance; rotating application sites is recommended to prevent local skin irritation, not to prevent tolerance.
Option D: Option D is incorrect: transdermal NTG achieves therapeutic plasma concentrations reliably during the wear period; adding oral nitrates would extend rather than interrupt nitrate exposure and worsen tolerance.
Option E: Option E is incorrect: tolerance with continuous nitrate exposure develops within 24–48 hours, not months; there is no established pharmacogenomic basis for the timeline described.
5. Which of the following correctly describes the contraindication between organic nitrates and phosphodiesterase type 5 (PDE5) inhibitors?
A) The combination is a relative contraindication; nitrates may be administered at half-dose under hemodynamic monitoring if the patient took sildenafil more than 12 hours ago
B) The contraindication applies only to intravenous nitroglycerin; sublingual nitroglycerin is safe at any interval after PDE5 inhibitor use because its short duration limits cyclic GMP (cGMP) accumulation
C) The contraindication applies only to sildenafil and vardenafil; tadalafil has a different mechanism of PDE5 inhibition that does not interact with nitrate-induced cyclic GMP (cGMP) production
D) The combination is contraindicated because PDE5 inhibitors directly block nitric oxide (NO) release from organic nitrates, preventing the drug from reaching its target enzyme
E) The combination is an absolute contraindication for all nitrate formulations and all PDE5 inhibitors; nitrates must be withheld for at least 24 hours after sildenafil or vardenafil, and at least 48 hours after tadalafil, due to its longer half-life of approximately 17.5 hours
ANSWER: E
Rationale:
The correct answer is E. Phosphodiesterase type 5 (PDE5) is the enzyme that degrades cyclic GMP (cGMP) in vascular smooth muscle. Organic nitrates generate nitric oxide (NO), which activates soluble guanylyl cyclase (sGC) to produce cGMP. PDE5 inhibitors prevent cGMP breakdown. The combination produces dramatically potentiated and prolonged cGMP accumulation in vascular smooth muscle, causing severe and potentially fatal systemic vasodilation and hypotension. The contraindication is absolute — no dose adjustment or monitoring protocol renders the combination safe within the time windows. Mandatory nitrate-free intervals after PDE5 inhibitor use are: 24 hours for sildenafil (Viagra, Revatio) and vardenafil (Levitra), which have plasma half-lives of approximately 4 hours; and 48 hours for tadalafil (Cialis), which has a plasma half-life of approximately 17.5 hours. The contraindication applies to all nitrate formulations regardless of route — sublingual, oral, transdermal, and intravenous.
Option A: Option A is incorrect: the PDE5 inhibitor-nitrate interaction is an absolute, not relative, contraindication; no half-dose protocol or monitoring strategy renders it safe within the contraindication window.
Option B: Option B is incorrect: the absolute contraindication applies to all nitrate formulations, including sublingual nitroglycerin; the short duration of sublingual NTG does not mitigate the pharmacodynamic cGMP potentiation that occurs at the vascular smooth muscle level.
Option C: Option C is incorrect: tadalafil acts by the same mechanism as sildenafil and vardenafil — PDE5 inhibition preventing cGMP degradation — and carries the same absolute contraindication with nitrates, requiring an even longer 48-hour window due to its prolonged half-life.
Option D: Option D is incorrect: PDE5 inhibitors do not block NO release from organic nitrates; they act downstream by preventing cGMP degradation, not upstream by interfering with NO generation.
6. A 70-year-old man receiving high-dose intravenous nitroglycerin develops cyanosis unresponsive to 100% oxygen. Pulse oximetry reads 85% despite adequate ventilation. Which of the following is the correct diagnosis and treatment?
A) Carbon monoxide poisoning causing carboxyhemoglobin; administer 100% normobaric oxygen and arrange hyperbaric oxygen therapy
B) Pulmonary edema causing ventilation-perfusion mismatch; administer intravenous furosemide and reduce the NTG infusion rate
C) Methemoglobinemia from nitrate-mediated oxidation of ferrous hemoglobin (Fe2+) to ferric methemoglobin (Fe3+), which cannot carry oxygen; administer methylene blue 1–2 mg/kg intravenously
D) Cyanide toxicity from organic nitrate metabolite accumulation; administer hydroxocobalamin 5 g intravenously
E) Bronchospasm from nitrate-induced histamine release causing severe ventilation-perfusion mismatch; administer inhaled salbutamol (albuterol) and discontinue NTG
ANSWER: C
Rationale:
The correct answer is C. Organic nitrates oxidize ferrous hemoglobin (Fe2+) to ferric methemoglobin (Fe3+). Methemoglobin cannot carry oxygen and causes a leftward shift of the oxyhemoglobin dissociation curve in remaining functional hemoglobin, impairing tissue oxygen delivery. The clinical result is cyanosis that does not improve with supplemental oxygen — because oxygen is being delivered to the alveoli normally but hemoglobin cannot transport it. Pulse oximetry reads approximately 85% regardless of actual saturation because the standard two-wavelength oximeter cannot distinguish methemoglobin from oxyhemoglobin and defaults to this intermediate spurious value; co-oximetry using multiple wavelengths is required for accurate diagnosis. Methemoglobinemia is clinically significant at high-dose IV-NTG (greater than 5 mcg/kg/min for prolonged periods) or with concurrent oxidizing agents such as dapsone or benzocaine. Treatment is methylene blue 1–2 mg/kg intravenously, which reduces methemoglobin back to functional hemoglobin via NADPH-dependent methemoglobin reductase.
Option A: Option A is incorrect: carbon monoxide poisoning causes a near-normal (not 85%) pulse oximetry reading because standard oximetry reads carboxyhemoglobin as oxyhemoglobin; the clinical context of high-dose IV-NTG and the characteristic 85% artifact identify methemoglobinemia.
Option B: Option B is incorrect: IV-NTG is a potent venodilator used to treat pulmonary edema — it does not cause it. Ventilation-perfusion mismatch from pulmonary edema would not produce the characteristic 85% oximetry artifact.
Option D: Option D is incorrect: cyanide toxicity is associated with sodium nitroprusside metabolism, not organic nitrate metabolism; it presents with lactic acidosis, altered mental status, and cardiovascular collapse, not isolated hemoglobin oxidation.
Option E: Option E is incorrect: organic nitrates do not cause histamine-mediated bronchospasm; bronchospasm would not explain the characteristic hemoglobin oxidation pattern or the 85% pulse oximetry artifact.
7. A 62-year-old man started on long-acting isosorbide mononitrate develops an increase in resting heart rate from 70 to 88 beats per minute. Which of the following correctly explains the mechanism and required management?
A) Baroreceptor-mediated sympathetic activation in response to nitrate-induced blood pressure reduction increases heart rate and contractility, partially negating the anti-ischemic benefit of preload reduction; a beta-blocker or non-dihydropyridine calcium channel blocker (CCB) is required to suppress this reflex
B) Direct nitrate stimulation of beta-1 adrenoceptors in the sinoatrial node via cyclic GMP (cGMP) causes tachycardia; the addition of ivabradine selectively blocks the funny current (If) to restore normal rate without affecting blood pressure
C) Nitrate-induced depletion of cardiac acetylcholine stores reduces vagal inhibitory tone at the sinoatrial node, causing relative sympathetic predominance; the addition of pyridostigmine restores cholinergic balance
D) The tachycardia reflects nitrate-induced hyperthyroidism from iodine released during nitroglycerin metabolism; thyroid function testing and dose reduction are required
E) The tachycardia is caused by nitrate-induced hypokalemia from renal potassium wasting, which depolarizes the sinoatrial node membrane potential; potassium supplementation and an ECG are required
ANSWER: A
Rationale:
The correct answer is A. Organic nitrates produce venodilation and, at higher doses, arteriolar dilation that lowers blood pressure. Baroreceptors in the carotid sinus and aortic arch detect the fall in arterial pressure and trigger a reflex increase in sympathetic nervous system outflow: heart rate and myocardial contractility rise through beta-1 adrenergic receptor activation at the sinoatrial node and myocardium. This baroreceptor-mediated reflex tachycardia is a predictable pharmacological consequence of vasodilator therapy. It is clinically important because heart rate is a primary determinant of myocardial oxygen demand (MVO2 is proportional to heart rate × contractility × wall stress), so the reflex tachycardia partially counteracts the anti-ischemic benefit of nitrate-induced preload reduction. The required management is a beta-blocker — which blocks the beta-1 sympathetic response — or a non-dihydropyridine CCB (verapamil or diltiazem), which slows heart rate by inhibiting sinoatrial and atrioventricular nodal conduction. This combination is standard in stable angina management.
Option B: Option B is incorrect: nitrates have no direct beta-1 adrenoceptor agonist activity; cGMP does not stimulate cardiac pacemaker cells. Ivabradine is a reasonable rate-limiting agent in some patients but is not the first-line response to nitrate-induced reflex tachycardia.
Option C: Option C is incorrect: nitrates do not deplete cardiac acetylcholine stores or reduce vagal tone; the tachycardia is driven by sympathetic activation, not parasympathetic withdrawal.
Option D: Option D is incorrect: nitroglycerin does not contain iodine and does not affect thyroid function; drug-induced hyperthyroidism is not a recognized adverse effect of organic nitrates.
Option E: Option E is incorrect: organic nitrates do not cause renal potassium wasting or hypokalemia; the tachycardia is hemodynamically mediated via the baroreceptor reflex, not from electrolyte disturbance.
8. Which of the following correctly describes the pharmacokinetic property of oral isosorbide dinitrate (ISDN) that makes it less predictable than isosorbide mononitrate (ISMN) for chronic stable angina management?
A) ISDN has a plasma half-life of less than 30 minutes, requiring dosing every two hours to maintain therapeutic plasma concentrations throughout the waking day
B) ISDN is poorly absorbed from the gastrointestinal tract due to its high molecular weight, resulting in variable and unpredictable peak plasma concentrations after each dose
C) ISDN undergoes extensive renal elimination that varies with creatinine clearance, making dose adjustment necessary in all patients with chronic kidney disease
D) ISDN undergoes approximately 75% first-pass hepatic extraction, yielding an oral bioavailability of only approximately 25% with significant interpatient variability due to differences in hepatic blood flow and enzyme expression
E) ISDN is a highly protein-bound drug that is displaced by commonly co-prescribed cardiac medications including beta-blockers and statins, causing unpredictable free drug concentrations
ANSWER: D
Rationale:
The correct answer is D. Isosorbide dinitrate (ISDN) undergoes extensive first-pass hepatic extraction — approximately 75% of an oral dose is metabolized before reaching the systemic circulation. The resulting oral bioavailability of approximately 25% is not only low but highly variable between patients, because first-pass extraction depends on hepatic blood flow and cytochrome enzyme expression, both of which vary substantially between individuals. A fixed oral dose of ISDN can therefore produce markedly different plasma concentrations and clinical effects in different patients, making titration to a reliable anti-ischemic effect difficult. This pharmacokinetic limitation is the primary reason ISDN has been largely supplanted by isosorbide mononitrate (ISMN), which is already the active mononitrate form, undergoes negligible first-pass hepatic metabolism, and achieves approximately 100% oral bioavailability with highly consistent and predictable plasma concentrations.
Option A: Option A is incorrect: ISDN's plasma half-life for the parent compound is approximately 1 hour, and its active mononitrate metabolites extend the pharmacological duration to 4–6 hours; twice-daily eccentric dosing (not two-hourly dosing) is the standard regimen.
Option B: Option B is incorrect: ISDN is a small lipophilic molecule with adequate gastrointestinal absorption; the pharmacokinetic problem is hepatic first-pass extraction after absorption, not poor absorption itself.
Option C: Option C is incorrect: ISDN and its active metabolites are primarily eliminated by hepatic metabolism, not renal excretion; renal dose adjustment is not routinely required for ISDN.
Option E: Option E is incorrect: significant protein displacement interactions between ISDN and beta-blockers or statins are not a recognized clinical pharmacokinetic concern; the unpredictability of ISDN plasma concentrations is driven by first-pass hepatic extraction variability, not protein binding displacement.
9. A 72-year-old man presents with an acute inferior STEMI and blood pressure of 82/58 mmHg. Right-sided leads show ST elevation in V4R. Which of the following correctly identifies the contraindication to nitroglycerin and the correct management of his hypotension?
A) Nitroglycerin is contraindicated because the systolic blood pressure is below 90 mmHg, which is a standard threshold contraindication for all vasodilators; the hypotension should be treated with norepinephrine infusion to restore perfusion pressure
B) ST elevation in V4R indicates right ventricular (RV) infarction; the RV is preload-dependent and nitroglycerin-induced venodilation will reduce venous return and collapse right ventricular output; hypotension should be treated with isotonic saline volume loading to increase right ventricular preload
C) Nitroglycerin is contraindicated in all inferior STEMI presentations regardless of right ventricular involvement because inferior infarction increases sensitivity to nitrate-induced coronary steal from the right coronary artery territory
D) Nitroglycerin is contraindicated because inferior STEMI is always associated with concurrent PDE5 inhibitor use in this age group; the hypotension indicates a nitrate-PDE5 interaction requiring IV calcium gluconate as the antidote
E) Nitroglycerin is contraindicated because it will worsen the AV block commonly associated with inferior STEMI by adding nitrate-induced vagal activation to the existing conduction disease; atropine should be administered first
ANSWER: B
Rationale:
The correct answer is B. ST elevation in lead V4R (right-sided precordial lead) is the diagnostic finding of right ventricular (RV) infarction, which complicates approximately 30–50% of inferior wall STEMIs due to proximal right coronary artery occlusion involving the RV marginal branches. The infarcted right ventricle cannot generate normal contractile force and becomes critically dependent on preload — venous return and right ventricular filling pressure — to maintain output across the pulmonary vasculature and into the left heart. Nitroglycerin's primary hemodynamic action is venodilation with reduction in venous return. In RV infarction, removing preload reserve collapses right ventricular output, reduces pulmonary blood flow, eliminates left ventricular filling, and causes precipitous systemic hypotension. The correct management is the opposite of vasodilation: isotonic saline (0.9% NaCl) volume loading to increase right ventricular preload and restore output. Nitroglycerin must be withheld entirely.
Option A: Option A is incorrect: while SBP below 90 mmHg is a general caution for nitrate use, the specific absolute contraindication here is RV infarction physiology — preload dependence. Volume loading rather than vasopressors is the correct initial treatment because the problem is insufficient preload, not reduced vasomotor tone.
Option C: Option C is incorrect: IV-NTG is recommended (ACC/AHA Class I) for persistent ischemic symptoms and pulmonary congestion in most STEMI presentations; the contraindication is specific to confirmed right ventricular infarction.
Option D: Option D is incorrect: concurrent PDE5 inhibitor use is a separate contraindication requiring direct questioning, but it is not assumed from patient demographics, and calcium gluconate is not the antidote for the nitrate-PDE5 interaction.
Option E: Option E is incorrect: nitroglycerin does not activate vagal tone at the AV node; AV block in inferior STEMI is caused by ischemia of the AV nodal artery (usually from the right coronary artery), not by nitrate administration.
10. A 64-year-old man with stable angina and multi-vessel coronary artery disease is on aspirin, atorvastatin, metoprolol succinate, and isosorbide mononitrate. He asks his physician which of these medications reduces his risk of heart attack. Regarding the isosorbide mononitrate specifically, which of the following is correct?
A) Isosorbide mononitrate reduces myocardial infarction risk through its modest antiplatelet effect, which additive to aspirin provides superior thrombus prevention in stenotic coronary segments
B) Isosorbide mononitrate reduces cardiovascular mortality in stable coronary artery disease, with the greatest benefit in patients with left ventricular dysfunction
C) Isosorbide mononitrate prevents myocardial infarction by stabilizing vulnerable coronary plaques through sustained nitric oxide (NO)-mediated suppression of vascular inflammation
D) Isosorbide mononitrate reduces sudden cardiac death risk in stable coronary artery disease by preventing coronary vasospasm, which is a common trigger of fatal arrhythmias
E) Isosorbide mononitrate reduces anginal frequency and improves exercise tolerance but has not been demonstrated to reduce mortality or myocardial infarction in stable coronary artery disease; it is a purely anti-ischemic and anti-anginal agent
ANSWER: E
Rationale:
The correct answer is E. Long-acting organic nitrates — including isosorbide mononitrate, isosorbide dinitrate, and transdermal nitroglycerin — effectively reduce anginal episode frequency, increase exercise duration before ischemic threshold, and improve quality of life in stable coronary artery disease. However, no randomized controlled trial has demonstrated that long-acting nitrates reduce mortality, myocardial infarction, or other hard cardiovascular endpoints in stable CAD. Their pharmacological mechanism — venodilation reducing preload and wall stress, epicardial coronary vasodilation, and modest platelet inhibition — does not translate to the plaque-stabilizing, anti-thrombotic, or mortality-reducing benefits of beta-blockers (post-MI), ACE inhibitors, statins, or antiplatelet agents. In this patient's regimen, aspirin provides antiplatelet protection, atorvastatin provides plaque stabilization and mortality reduction, and metoprolol provides heart rate reduction and mortality benefit post-MI or in heart failure — isosorbide mononitrate contributes symptom control and functional improvement only.
Option A: Option A is incorrect: while nitrates modestly inhibit platelet aggregation via cGMP elevation, this effect is not clinically meaningful for MI prevention and has not been shown to reduce events when added to aspirin.
Option B: Option B is incorrect: no outcome trial has demonstrated cardiovascular mortality reduction with long-acting nitrates in stable CAD with or without left ventricular dysfunction; ACE inhibitors and beta-blockers carry this indication, not nitrates.
Option C: Option C is incorrect: while NO has anti-inflammatory properties in vitro, long-acting nitrate therapy has not been shown to stabilize vulnerable plaques or reduce MI risk through any mechanism in clinical trial evidence.
Option D: Option D is incorrect: while nitrates reduce vasospastic angina attacks, no trial has demonstrated that they reduce sudden cardiac death from coronary vasospasm-triggered arrhythmia in the stable CAD population.
11. A physician prescribes isosorbide mononitrate immediate-release (ISMN-IR) 20 mg twice daily to a patient with stable angina. Which of the following dosing schedules correctly implements the nitrate-free interval, and which common schedule must be explicitly avoided?
A) Correct schedule: 6:00 AM and 6:00 PM; avoid: 8:00 AM and 8:00 PM, because the later schedule reduces morning anti-ischemic coverage during peak angina risk hours
B) Correct schedule: 12:00 PM and 8:00 PM; avoid: 8:00 AM and 12:00 PM, because morning dosing produces excessive hypotension during the high-sympathetic-tone early morning hours
C) Correct schedule: 7:00 AM and 2:00 PM, providing an overnight nitrate-free interval of approximately 10–12 hours; explicitly avoid 7:00 AM and 7:00 PM, which eliminates the overnight nitrate-free interval and causes tolerance within 24–48 hours
D) Correct schedule: 7:00 AM and 7:00 PM; avoid: 7:00 AM and 2:00 PM, because the afternoon dose wears off too early, leaving the patient without nitrate coverage during evening hours when angina is most common
E) Correct schedule: 8:00 AM and 10:00 PM; avoid: any schedule with less than a 12-hour gap between doses, because ISMN-IR requires exactly 12 hours of drug effect followed by 12 hours of nitrate-free interval
ANSWER: C
Rationale:
The correct answer is C. Isosorbide mononitrate immediate-release (ISMN-IR) has a duration of action of approximately 6–8 hours. The correct eccentric dosing schedule is the first dose at 7:00 AM and the second dose at 2:00 PM. With this schedule, the second dose's pharmacological effect wanes by approximately 8:00–10:00 PM, providing a nitrate-free interval of approximately 10–12 hours through the evening and overnight. This interval allows regeneration of mitochondrial aldehyde dehydrogenase 2 (ALDH2) and resolution of neurohormonal pseudotolerance, restoring full nitrate efficacy by the following morning. The schedule to explicitly avoid is 7:00 AM and 7:00 PM — the most common prescribing error with ISMN-IR. Although the 12-hour symmetrical interval appears logical, the second dose at 7:00 PM extends drug effect through approximately 1:00–3:00 AM, eliminating the overnight nitrate-free interval and causing tolerance to develop within 24–48 hours. Patients prescribed the 7:00 AM / 7:00 PM schedule predictably report loss of efficacy within the first week.
Option A: Option A is incorrect: the 6:00 AM / 6:00 PM schedule has the same problem as 7:00 AM / 7:00 PM — the evening dose eliminates the overnight nitrate-free interval; avoidance of the 8:00 AM / 8:00 PM schedule for the stated reason is pharmacologically incorrect.
Option B: Option B is incorrect: 12:00 PM and 8:00 PM does not provide meaningful anti-ischemic coverage during the highest-risk morning period (6:00–10:00 AM) and is not a clinically recommended ISMN-IR regimen.
Option D: Option D is incorrect: 7:00 AM and 7:00 PM is explicitly the wrong schedule — it eliminates the nitrate-free interval and causes tolerance; describing it as correct inverts the pharmacological rationale.
Option E: Option E is incorrect: ISMN-IR does not require 12 hours of drug effect followed by 12 hours free; the drug's 6–8 hour duration with a 7-hour dosing interval between the two doses provides 14–16 hours of coverage and a 10–12 hour nitrate-free interval — not a 12/12 split.
12. When preparing an intravenous nitroglycerin (IV-NTG) infusion, which tubing requirement must be met and why?
A) Non-polyvinyl chloride (PVC) tubing must be used because nitroglycerin adsorbs to the inner walls of standard PVC administration sets, significantly reducing the dose delivered to the patient and making accurate hemodynamic titration unreliable
B) Microfiltered tubing with a 0.22-micron inline filter must be used because nitroglycerin precipitates into microparticles at infusion rates below 50 mcg/min that can cause pulmonary microembolism
C) Light-protected amber tubing must be used because nitroglycerin undergoes photodegradation in clear tubing at a rate of approximately 30% per hour under standard ward lighting conditions
D) Heated tubing maintained at 37°C must be used because nitroglycerin crystallizes in standard tubing at room temperature, causing flow obstruction and unpredictable drug delivery
E) Standard PVC tubing is acceptable provided the infusion rate exceeds 20 mcg/min; below this rate, non-PVC tubing is required because adsorption becomes proportionally more significant at slow flow rates
ANSWER: A
Rationale:
The correct answer is A. Nitroglycerin has high affinity for polyvinyl chloride (PVC), the material used in standard intravenous administration sets. The drug adsorbs onto the inner surface of PVC tubing, and a clinically significant fraction of the prescribed dose never reaches the patient. The magnitude of loss depends on NTG concentration, flow rate, and tubing length, but can be substantial — potentially delivering far less drug than the infusion pump rate implies. Since IV-NTG is titrated to hemodynamic effect (target blood pressure reduction, symptom relief, preload reduction), unreliable drug delivery makes accurate and safe titration impossible. Non-PVC tubing — polyethylene or polyolefin administration sets — eliminates adsorption and ensures dose delivery corresponds to the prescribed infusion rate. This is a mandatory preparation step for every IV-NTG order.
Option B: Option B is incorrect: nitroglycerin does not precipitate into microparticles at clinical infusion rates; the drug remains in solution across the clinical dosing range and does not require inline filtration for this reason.
Option C: Option C is incorrect: while nitroglycerin solutions can degrade with prolonged light exposure, this is managed by appropriate storage of the prepared infusion bag; per-hour photodegradation in standard tubing at the rate described is not an established clinical concern, and light-protected tubing is not the primary mandatory requirement.
Option D: Option D is incorrect: nitroglycerin does not crystallize in standard IV tubing at room temperature under clinical infusion conditions; temperature-dependent crystallization is not a recognized clinical preparation concern for IV-NTG.
Option E: Option E is incorrect: the PVC adsorption problem occurs across all infusion rates — there is no threshold rate above which standard PVC tubing becomes acceptable. Non-PVC tubing is required regardless of the infusion rate prescribed.
13. Which of the following correctly identifies the primary molecular mechanism of organic nitrate tolerance?
A) Downregulation of soluble guanylyl cyclase (sGC) expression in vascular smooth muscle after sustained nitric oxide (NO) exposure, reducing the capacity to generate cyclic GMP (cGMP) from GTP
B) Upregulation of phosphodiesterase type 5 (PDE5) in vascular smooth muscle during continuous nitrate exposure, accelerating cyclic GMP (cGMP) degradation and reducing the net vasodilatory signal
C) Neurohormonal activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) in response to nitrate-induced hypotension, causing sodium retention and vasoconstriction that counteract the nitrate effect
D) Oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) by superoxide and peroxynitrite generated as byproducts of nitroglycerin bioactivation, reducing the enzymatic capacity to convert nitroglycerin to nitric oxide (NO)
E) Competitive inhibition of ALDH2 by endogenous aldehydes that accumulate during continuous nitrate metabolism, reversibly occupying the enzyme active site and reducing nitroglycerin bioactivation
ANSWER: D
Rationale:
The correct answer is D. The primary molecular mechanism of organic nitrate tolerance is oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2). During nitroglycerin (GTN) bioactivation, ALDH2 catalyzes the denitration of GTN, generating inorganic nitrite and subsequently nitric oxide (NO). This reaction produces reactive oxygen species as byproducts — superoxide and peroxynitrite — that oxidatively and irreversibly damage ALDH2 itself. The enzyme required to generate NO is progressively destroyed by the very process of generating it, creating a self-limiting cycle in which continued nitrate administration produces progressively less NO and diminishing vasodilatory response. This mechanism is specific to ALDH2-dependent nitrates (GTN and ISDN); it is the primary mechanism and is supported by the most direct experimental evidence, including studies showing that ALDH2 activity falls markedly during GTN infusion and is restored during the nitrate-free interval.
Option A: Option A is incorrect: sGC downregulation has been proposed as a contributing molecular adaptation in chronic NO exposure but is not the established primary mechanism; experimental evidence places ALDH2 inactivation as the primary driver of tolerance.
Option B: Option B is incorrect: PDE5 upregulation is a proposed secondary adaptation but is not the primary established mechanism; furthermore, PDE5 inhibitors are absolutely contraindicated with nitrates and cannot be used to reverse this adaptation clinically.
Option C: Option C is incorrect: neurohormonal RAAS and SNS activation is the mechanism of pseudotolerance — the secondary component of nitrate tolerance. While clinically important, it is a systemic counterregulatory response, not the primary molecular mechanism; it is partially reversible with ACE inhibitors or spironolactone, unlike the primary ALDH2 inactivation.
Option E: Option E is incorrect: the oxidative inactivation of ALDH2 is covalent and irreversible within the tolerance time frame, not a reversible competitive inhibition by endogenous aldehyde substrates; endogenous aldehyde accumulation is not the established mechanism of ALDH2 inactivation during nitrate tolerance.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.